NewAmsterdam Pharma Company N.V. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 9.56 million compared to EUR 93.5 million a year ago. Net loss was EUR 75.1 million compared to net income of EUR 54.51 million a year ago.

Basic loss per share from continuing operations was EUR 0.92 compared to basic earnings per share from continuing operations of EUR 1.5 a year ago. Diluted loss per share from continuing operations was EUR 0.92 compared to diluted earnings per share from continuing operations of EUR 1.35 a year ago.